Sweden bolsters biotech
Enlarge image

BusinessSweden

Sweden bolsters biotech

05.04.2012 - Swedish pharma company Astra Zeneca plus Wallenberg Foundation and Swedish government pledge a record investment into the biotech industry.

Stockholm – Under a new initiative, AstraZeneca will invest €2.3m to €4.5m (SEK20m to SEK40m) a year over the next five years in early-stage research projects. The Wallenberg Foundation, a private financing institution which is dedicated to promoting scientific research and education in Sweden, will provide additional €25m (SEK220m). The money will be used to build up technology laboratories for the SciLifeLab collaboration between four Swedish universities. The contribution of the Swedish government is yet unknown, but a spokesperson already announced the government is planning a record investment in the country's life science infrastructure. The details would be published in the autumn budget. Jan Björklund, the Swedish Minister for Education, announced the SciLifeLab will become a national research institute for major research in molecular biosciences and bioinformatics. According to the government’s plan, SciLifeLab will grow to employ about 1,000 scientists and have a turnover of about €113m (SEK1bn) within a few years.  SciLifeLab is a joint venture between four universities; Karolinska Institutet, the Royal Institute of Technology, Stockholm University and Uppsala University. The medical research focuses on investigating the molecular basis of complex human diseases, and seeks to find biomarkers that can help diagnose diseases and monitor their progress. The vision is to make SciLifeLab a competitive centre for high-throughput biosciences with platforms in genomics, comparative genetics, proteomics, bioimaging and functional genomics as well as research communities in biology, medicine and environmental sciences.

.

http://www.european-biotechnology-news.com/news/news/2012-02/sweden-bolsters-biotech.html

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ADDEX3.30 CHF6.45%
  • PAION3.17 EUR3.93%
  • SANTHERA90.75 CHF3.07%

FLOP

  • WILEX2.36 EUR-12.27%
  • THERAMETRICS0.08 CHF-11.11%
  • CYTOS0.23 CHF-4.17%

TOP

  • CO.DON3.27 EUR30.8%
  • PAION3.17 EUR27.8%
  • EPIGENOMICS3.80 EUR22.6%

FLOP

  • MEDIGENE3.82 EUR-17.8%
  • ADDEX3.30 CHF-17.5%
  • EVOTEC3.10 EUR-15.5%

TOP

  • SANTHERA90.75 CHF2124.3%
  • CO.DON3.27 EUR280.2%
  • PAION3.17 EUR213.9%

FLOP

  • CYTOS0.23 CHF-94.3%
  • THERAMETRICS0.08 CHF-42.9%
  • BIOFRONTERA2.18 EUR-40.3%

No liability assumed, Date: 21.09.2014